Tesofensine
Weight management compound targeting neurotransmitters
Overview
Tesofensine is a triple monoamine reuptake inhibitor that was originally developed for Alzheimer and Parkinson diseases. It inhibits the reuptake of norepinephrine, dopamine, and serotonin, leading to significant appetite suppression and weight loss.
Mechanism of Action
Inhibits reuptake of norepinephrine, dopamine, and serotonin → increases satiety signaling → reduces appetite → enhances thermogenesis → modulates reward-driven eating behavior.
Benefits
- Potent appetite suppression
- Significant weight loss (~12%)
- Improved satiety
- Enhanced energy expenditure
- Addresses emotional eating
Dosing Protocol
Half-Life
~8 days
Duration of pharmacological activity after administration.
Side Effects
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Mood changes
- Elevated blood pressure
Stacking Recommendations
Storage & Reconstitution
Store at room temperature. Protect from moisture.
Research Notes
Phase 2 trials showed ~12.8% weight loss over 24 weeks. Cardiovascular safety concerns have slowed development. Being pursued in Denmark/Mexico for approval. Not FDA-approved.
Medical Disclaimer
This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment recommendations. Peptide therapy should only be initiated under the supervision of a qualified healthcare provider. Individual results may vary. Always consult with your physician before starting any new therapy. Regulatory status varies by jurisdiction.